evidence: In patients receiving bevacizumab plus lomustine combination therapy, patients had higher CECs after 4 weeks (P<0.001) and 6 weeks (P<0.001) of treatment compared with the baseline value.
intervention: bevacizumab 
comparator: baseline
outcome: circulating endothelial cells (CECs) after 4 and 6 weeks